Chugai Pharmaceutical Competitors and Similar CompaniesClear all
Chugai Pharmaceutical's competitors and similar companies include Symphogen, Epizyme, Loxo Oncology and Ascentage Pharma.
 Chugai Pharmaceutical Chugai Pharmaceutical is a pharmaceutical company specializing in the fields of oncology, as well as bone, joint, and renal diseases. |  Epizyme Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors. |  Loxo Oncology Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations. |  Ascentage Pharma Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies. | ||
Founding Date | Founding Date 1925 | Founding Date 2000 | Founding Date 2007 | Founding Date 2013 | Founding Date 2017 |
Type | Type Public | Type Private | Type Public | Type Subsidiary | Type Public |
Tags | |||||
Locations | Locations Chuo City, JP HQ Guangzhou Shi, CN Taizhou, CN Puteaux, FR Frankfurt Am Main, DE Singapore, SG see more | Locations Ballerup, DK HQ Somerville, US | Locations Cambridge, US HQ | Locations Stamford, US HQ Alcobendas, ES Boulder, US New York, US South San Francisco, US | Locations Suzhou, CN HQ Guangzhou Shi, CN Suzhou Shi, CN Taizhou, CN Rockville, US |
Employees | Employees 7,778 | Employees 196 | Employees 20364% increase | Employees 65610% decrease | Employees 567 |
Valuation ($) | Valuation ($) 78.7 b | Valuation ($) N/A | Valuation ($) 250.8 m | Valuation ($) N/A | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) ¥1.3t (FY, 2025) | Revenue (est.) N/A | Revenue (est.) $37.4m (FY, 2021) | Revenue (est.) N/A | Revenue (est.) ¥574.1m (FY, 2025) |
Cost of goods | Cost of goods ¥363.7b (FY, 2025) | Cost of goods N/A | Cost of goods $10.5m (FY, 2021) | Cost of goods N/A | Cost of goods ¥48.9m (FY, 2025) |
Gross profit | Gross profit ¥903.5b (FY, 2025) | Gross profit N/A | Gross profit N/A | Gross profit N/A | Gross profit ¥546.6m (FY, 2025) |
Net income | Net income ¥434b (FY, 2025) | Net income N/A | Net income ($251.1m) (FY, 2021) | Net income ($148.9m) (FY, 2017) | Net income (¥1.2b) (FY, 2025) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised $ 387.2m | Total funding raised $ 51.5m | Total funding raised $ 57m | Total funding raised $ 237.5m |
For sources of this data, please see the company profile
View Company Profiles
Symphogen
HQ
Ballerup, DK
Employees
196
Symphogen is a biotech company focused on oncology and immuno-oncology.
View companyEpizyme
HQ
Cambridge, US
Employees
203
Epizyme is a clinical stage biopharmaceutical company focusing on treatments for blood cancer and tumors.
View companyLoxo Oncology
HQ
Stamford, US
Loxo Oncology is a biopharmaceutical company focused on targeted cancer therapies for genetically-defined patient populations.
View companyAscentage Pharma
HQ
Suzhou, CN
Employees
567
Ascentage Pharma Group International (亚盛闘棄集團) is a biopharmaceutical company that is engaged in discovering, developing, and commercializing therapies.
View company